Inoviq Ltd IIQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.47
- Day Range
- A$0.47–0.47
- 52-Week Range
- A$0.47–0.92
- Bid/Ask
- A$0.47 / A$0.47
- Market Cap
- A$51.86 Mil
- Volume/Avg
- 20,000 / 79,466
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 81.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 85
- Website
- https://www.bard1.com
Comparables
Valuation
|
Metric
|
IIQ
|
TIHE
|
300642
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 59.27 |
Price/Book Value | 2.48 | — | 1.63 |
Price/Sales | 81.17 | — | 5.01 |
Price/Cash Flow | — | — | 16.41 |
Price/Earnings
IIQ
TIHE
300642
Financial Strength
|
Metric
|
IIQ
|
TIHE
|
300642
|
|---|---|---|---|
Quick Ratio | 6.85 | 0.00 | 6.08 |
Current Ratio | 7.07 | 0.00 | 7.48 |
Interest Coverage | — | — | 101.44 |
Quick Ratio
IIQ
TIHE
300642
Profitability
|
Metric
|
IIQ
|
TIHE
|
300642
|
|---|---|---|---|
Return on Assets (Normalized) | −31.91% | — | 2.44% |
Return on Equity (Normalized) | −34.90% | — | 2.73% |
Return on Invested Capital (Normalized) | −35.20% | — | 2.41% |
Return on Assets
IIQ
TIHE
300642
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Gjnnymzpp | Xtnwr | $228.7 Bil | |||
| Danaher Corp
DHR
| Lrzkzxrl | Lnxqnv | $195.0 Bil | |||
| IQVIA Holdings Inc
IQV
| Ynlzqzwlm | Lzfysz | $41.9 Bil | |||
| Agilent Technologies Inc
A
| Bryyssgbq | Hnr | $41.7 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Rfkhrmhj | Hrnn | $39.3 Bil | |||
| Mettler-Toledo International Inc
MTD
| Qrkxztvvfj | Kvyqgm | $30.8 Bil | |||
| Icon PLC
ICLR
| Bwtqttkv | Lpkgdv | $24.3 Bil | |||
| Illumina Inc
ILMN
| Rrnwrph | Dxrdsq | $22.5 Bil | |||
| Waters Corp
WAT
| Cflwdxrq | Rblh | $20.9 Bil | |||
| Labcorp Holdings Inc
LH
| Xfhcnhyd | Jmnbb | $18.1 Bil |
United States